CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022

Rhea-AI Summary

CinCor Pharma, Inc. (NASDAQ: CINC) will report its fourth quarter and full year 2021 financial results before the U.S. markets open on March 22, 2022. A conference call will occur at 8:30 AM Eastern Time to discuss the outcomes and business updates.

CinCor specializes in developing CIN-107, a selective oral inhibitor targeting aldosterone synthase for hypertension and other cardio-renal diseases. The live conference call can be accessed through the company’s website with a replay available for 30 days post-call.

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, March 22, 2022. Following the announcement, the Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Tuesday, March 22, 2022
Time:	8:30 AM Eastern Time
Domestic:	877-407-9039
International:	201-689-8470
Conference ID:	13727506
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1533175&tp_key=c99580e1e

A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the CinCor Pharma, Inc. website or at the URL above. A replay will be available on the website approximately two hours following the live call for 30 days following the call. To access the live webcast, or the subsequent archived recording, please visit the Investors section of the CinCor website at www.CinCor.com.

About CinCor

CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.

Contacts:
Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO

Investors:
Bob Yedid
LifeSci Advisors
ir@CinCor.com

FAQ

When will CinCor Pharma report its financial results for Q4 2021?

CinCor Pharma will report its fourth quarter and full year 2021 financial results on March 22, 2022.

What is the focus of CinCor Pharma's lead candidate CIN-107?

CIN-107 is focused on treating hypertension and other cardio-renal diseases.

What time is CinCor Pharma's conference call on March 22, 2022?

The conference call is scheduled for 8:30 AM Eastern Time.

How can I access the CinCor Pharma conference call?

The conference call can be accessed via the Investors section on CinCor's website or through the provided webcast link.